Trial Profile
[18F]-T807 PET/CT Imaging of Tau Pathology in Young Onset Focal Dementia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Apr 2019
Price :
$35
*
At a glance
- Drugs Flortaucipir-F-18 (Primary)
- Indications Alzheimer's disease; Dementia; Primary progressive aphasia
- Focus Diagnostic use
- 22 Feb 2019 Status changed from active, no longer recruiting to completed.
- 24 Jan 2018 Planned End Date changed from 1 Dec 2018 to 31 Jan 2019.
- 24 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.